The Computational Analysis of Novel Drug Opportunities (CANDO) platform is a computational approach to make drug discovery faster and less expensive while also being safe and effective. UB researchers ...

insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, ...

Cambridge, Massachusetts, January 14, 2025 - Insilico Medicine (“Insilico”, HKEX:03696), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the ...

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.

TOKYO--(BUSINESS WIRE)--Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix ...

Synfini, Inc., provider of the industry’s most advanced Agile AI Foundry for drug discovery, today announced the launch of Fast Pass I, an open, rapid cloud workflow system which provides qualified ...

Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. The round was led by Bessemer ...

Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world's first agentic genomic drug dis ...

TandemAI's web-based platform, TandemViz, allows the integration and visualization of experimental data alongside computational analyses. The platform also allows end users to integrate disparate ...

Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic ...

The Computational Analysis of Novel Drug Opportunities (CANDO) platform is a computational approach to make drug discovery faster and less expensive while also being safe and effective. UB researchers ...